JNJ 0237
Alternative Names: JNJ-0237Latest Information Update: 28 Apr 2023
At a glance
- Originator Johnson & Johnson
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autosomal dominant polycystic kidney disease
Most Recent Events
- 26 Apr 2023 Phase-I clinical trials in Autosomal dominant polycystic kidney disease in unknown location (unspecified route) prior to April 2023 (Johnson & Johnson pipeline, April 2023)